Results 81 to 90 of about 296,448 (281)
Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis
Arthritis &Rheumatology, EarlyView.Objective
Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are overlapping yet distinct conditions within the SpA spectrum. As divergent immunophenotypes may influence disease course and therapeutic response, we compared immune cell subsets, cytokine profiles, and inflammatory mediators.Natalie Frede, Nils Craig‐Müller, Silke Kohrt, Marei‐Theresa Bott, Ulrich Salzer, Ana Cecilia Venhoff, Jens Thiel, Julia Frede, Reinhard E. Voll, Marta Rizzi, Raquel Lorenzetti, Nils Venhoff +11 morewiley +1 more sourceCOVID-19 in patients with psoriasis: A Latin American case series
JAAD International, 2021 Isabela Campo-Slebi, MD, María Fernanda Meza-Corso, MD, Paola Cárdenas, MD, Juan Raúl Castro-Ayarza, MD, Cesar González, MD, Carolina Cortés, MD, Manuel Franco, MD, Fernando Valenzuela, MD +7 moredoaj +1 more sourceEarly Psoriatic Arthritis
The Journal of Rheumatology Supplement, 2009 Early detection of psoriatic arthritis (PsA) can effectively help in reducing the risk of joint damage and disability. Accordingly, the authors offer diagnostic insights in order to improve the approach to the patient's medical history, clinical examination, and the imaging modalities.Scarpa R., Atteno M., Costa L., Peluso R., Iervolino S., Caso F., Del Puente A. +6 moreopenaire +4 more sourcesPharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study
Arthritis &Rheumatology, EarlyView.Objective
The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods
Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, the Paediatric Rheumatology International Trials Organisation (PRINTO); the Pediatric Rheumatology Collaborative Study Group (PRCSG), Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Alberto Martini, Daniel L. Lovell, Nicolino Ruperto +52 morewiley +1 more sourceCLINICAL OUTCOME MEASURES OF PSORIASIS
Reumatismo, 2011 Several tools have been introduced in clinical trials to quantify the severity and the response to a given therapeutic regimen of both psoriasis and psoriatic arthritis. Each method present specific advantages and limitations.E. Berardesca, C. Bonifatidoaj +1 more sourceDeucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial
Arthritis &Rheumatology, EarlyView.Objective
To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods
In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar +20 morewiley +1 more sourcePredicting Psoriatic Arthritis in Psoriasis Patients - A Swiss Registry Study.
Background
Psoriatic arthritis (PsA) is a prevalent comorbidity among patients with psoriasis, heavily contributing to their burden of disease, usually diagnosed several years after the diagnosis of psoriasis.Objectives
To investigate the predictability ...Wu, Jashin J, Boehncke, Wolf-Henning, Petersen, Troels C, Thyssen, Jacob P, Erik Kristensen, Lars, Cozzio, Antonio, Thomsen, Simon F, Navarini, Alexander A, Maul, Julia-Tatjana, Maul, Lara Valeska, Yawalkar, Nikhil, Micheroli, Raphael, Schlapbach, Christoph, Kündig, Thomas, Conrad, Curdin, Egeberg, Alexander, Nielsen, Mia-Louise +16 morecore +2 more sourcesUpdated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions
Arthritis &Rheumatology, EarlyView.Objective
We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods
We conducted a retrospective cohort study using National Clinical Cohort Collaborative Lesley E. Jackson, A. Jerrod Anzalone, Kenneth G. Saag, Rahima Begum, AKM F. Rahman, Namrata Singh, Kaleb Michaud, Jasvinder A. Singh, Rena C. Patel, Maria I. Danila, on behalf of the National Clinical Cohort Collaborative Consortium, Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit Saha, Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew M. Southerland, Andrew T. Girvin, Anita Walden, Anjali Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, Brijesh Patel, G. Caleb Alexander, Carolyn T. Bramante, Cavin Ward‐Caviness, Charisse Madlock‐Brown, Christine Suver, Christopher G. Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff Takemoto, Dan Housman, Davera Gabriel, David A. Eichmann, Diego Mazzotti, Donald E. Brown, Eilis Boudreau, Elaine L. Hill, Emily Carlson Marti, Emily R. Pfaff, Evan French, Farrukh M. Koraishy, Federico Mariona, Fred Prior, George Sokos, Greg Martin, Harold P. Lehmann, Heidi Spratt, Hemalkumar B. Mehta, J. W. Awori Hayanga, Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica Yasmine Islam, Jin Ge, Joel Gagnier, Johanna J. Loomba, John B. Buse, Jomol Mathew, Joni L. Rutter, Julie A. McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell, Kellie M. Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Cato, Kimberly Murray, Kristin Kostka, Lavance Northington, Lee Pyles, Lesley Cottrell, Lili M. Portilla, Mariam Deacy, Mark M. Bissell, Marshall Clark, Mary Emmett, Matvey B. Palchuk, Melissa A. Haendel, Meredith Adams, Meredith Temple‐O'Connor, Michael G. Kurilla, Michele Morris, Nasia Safdar, Nicole Garbarini, Noha Sharafeldin, Ofer Sadan, Patricia A. Francis, Penny Wung Burgoon, Philip R. O. Payne, Randeep Jawa, Rebecca Erwin‐Cohen, Rena C. Patel, Richard A. Moffitt, Richard L. Zhu, Rishikesan Kamaleswaran, Robert Hurley, Robert T. Miller, Saiju Pyarajan, Sam G. Michael, Samuel Bozzette, Sandeep K. Mallipattu, Satyanarayana Vedula, Scott Chapman, Shawn T. O'Neil, Soko Setoguchi, Stephanie S. Hong, Steven G. Johnson, Tellen D. Bennett, Tiffany J. Callahan, Umit Topaloglu, Valery Gordon, Vignesh Subbian, Warren A. Kibbe, Wenndy Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang +127 morewiley +1 more sourceCLINICAL PRESENTATION OF PSORIATIC ARTHRITIS
Reumatismo, 2011 Psoriatic arthritis is a spondyloarthropathy, which occurs in patients with skin and/or nail psoriasis. Basing its characterization on morphological purposes, several types of arthritis have been described.M. Atteno, R. Peluso, R. Scarpadoaj +1 more source